Roche Holding AG RHHBF
479.97 USD -16.96 (-3.41%)
Regular-session close
483.07 Day range 483.26
375.00 52-week range 514.08
- YTD
- +7.71%
- 1 year
- +23.07%
News
businesswire.com Perficient Expands Its Innovation Center to Advance Roche Diagnostics' Molecular Laboratory Systems CLUJ-NAPOCA, Romania--(BUSINESS WIRE)--Perficient, in collaboration with Roche Diagnostics, announced the expansion of its dedicated innovation center in Cluj-Napoca, Romania.
prnewswire.com Roche receives FDA 510(k) clearance for new cobas® eplex respiratory pathogen panel 3, enabling labs to customize respiratory testing for local patient needs The new cobas ® eplex RP3 panel detects up to 19 viruses and bacteria, with newly added Bordetella pertussis and improved inclusivity of influenza A and SARS-CoV-2 strains, from a single sample to…
seekingalpha.com Roche: Valuation Leaves Limited Upside Roche delivered 7% Q3 sales growth at constant currency, although approximately CHF 180 million was attributable to shipments that had been brought forward in Japan. Pharmaceuticals performed well,…
seekingalpha.com Brown Advisory Flexible Equity Strategy: Q3 2026 Top Contributors And Detractors Microsoft Corporation was the portfolio's top contributor during the quarter. Suncor Energy outperformed the Index during the quarter. KLA Corporation traded lower during the quarter.
wsj.com Roche Targets Emerging Oncology Market With New Lung-Cancer Drug The Swiss drugmaker expects a pill it is developing to become the new standard treatment for an advanced form of lung cancer, and the company's first shot at an emerging field within the oncology…
reuters.com Roche says divarasib cut risk of death 44% in lung cancer trial Roche says divarasib cut risk of death 44% in lung cancer trial
businesswire.com Genentech's Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Divarasib demonstrated best-in-class efficacy in Phase III trial, advancing the standard of care in previously treated KRAS G12C-mutated lung…
globenewswire.com Roche's divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer Basel, 25 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today pivotal results from the phase III Krascendo 1 study, which demonstrated the superior efficacy of investigational…
businesswire.com Genentech Presents Interim Phase III Data Showing Sefaxersen Significantly Reduced Proteinuria in People With IgA Nephropathy (IgAN) SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today late-breaking oral presentation data from the ongoing Phase III…
globenewswire.com Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN) Basel, 23 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today late-breaking oral presentation data from the ongoing phase III IMAgINATION study in adults with primary IgA nephropathy…
seekingalpha.com Roche Holding AG (RHHBY) Q3 2026 Sales/Trading Call Transcript Roche Holding AG (RHHBY) Q3 2026 Sales/Trading Call Transcript
zacks.com Roche's 9M 2026 Sales Rise on Strong Drug Demand, Pipeline Advances Roche's sales rise 6% at constant exchange rates in the first nine months of 2026, as key drug growth offsets legacy product declines and pipeline advances.
wsj.com Roche Posts Higher Sales on Growth Across Pharma, Diagnostics Units Roche reiterated its full-year guidance and said it is prepared to launch its giredestrant breast-cancer pill later this year.
reuters.com Roche third quarter sales slightly beat expectations with growth across divisions Roche third quarter sales slightly beat expectations with growth across divisions
reuters.com Roche says experimental MS pill cuts relapses by 55% in late-stage trials Roche says experimental MS pill cuts relapses by 55% in late-stage trials
wsj.com Roche Partners With China's Hansoh in Deal That Could Top $15 Billion The Swiss drugmaker will assume responsibility for outside China, Hong Kong, Macau and Taiwan after the completion of early-stage clinical trials.
reuters.com Roche to unveil lung, breast cancer data at ESMO 2026 Roche to unveil lung, breast cancer data at ESMO 2026
zacks.com Roche Gets FDA Approval for Enspryng in Thyroid Eye Disease RHHBY wins FDA approval for Enspryng in thyroid eye disease, offering the first and only at-home subcutaneous treatment option for patients.
zacks.com 4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month AZN, RHHBY, PBYI and OLMA offer exposure to breast cancer drug sales growth, expanded treatment approvals and clinical milestones that could shape prospects.
zacks.com Roche Expands Obesity Pipeline With Rona's RNAi Candidate RHHBY expands its obesity pipeline with a novel RNAi candidate targeting ALK7, while advancing enicepatide and other late-stage drugs to strengthen its metabolic disease ambitions.
benzinga.com Nurix Therapeutics Enrolls First Patient In Phase 1b/2 Study Of Bexobrutideg Plus Venetoclax In Chronic Lymphocytic Leukemia Under Roche Collaboration First patient enrolled in cohort combining bexobrutideg with venetoclaxInitial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLLStrategy includes evaluation of…
benzinga.com Ionis Pharmaceuticals And Partner Roche Said Prespecified Interim Results From Phase 3 IMAgINATION Study Of Sefaxersen For Primary IgA Nephropathy Met Its Primary Endpoint Of Statistically Significant And Clinically Meaningful Improvements In Proteinuria Reduction Vs. Placebo At 37 Weeks – Sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential –– IgAN is a progressive kidney…
benzinga.com Roche And Nurix Partner To Co-Develop BTK Degrader Bexobrutideg In $2.3B Deal Spanning Blood Cancers, Immunology And Neurology Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignanciesCollaboration adds to Roche's oncology pipeline and offers potential…
benzinga.com 'FDA Clears First Blood Test Used In Diagnosing Alzheimer's Disease; New Test Provides Less Invasive Option, Reduces Reliance On Pet Scans And Increases Diagnosis Accessibility' - FDA https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease#:~:text=The%20Lumipulse%20G%20pTau217%2F%C3%9F,and%20symptoms%20of%20the%20disease.- benzinga.com Stocks That Hit 52-Week Highs On Tuesday
benzinga.com Stocks That Hit 52-Week Highs On Tuesday 
benzinga.com Stocks That Hit 52-Week Highs On Friday - benzinga.com Stocks That Hit 52-Week Highs On Monday
- benzinga.com Stocks That Hit 52-Week Highs On Tuesday
- benzinga.com Stocks That Hit 52-Week Highs On Monday